A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis

Официальное название

A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients With Intermediate or High-Risk Primary or Secondary Myelofibrosis

Обзор

This study is a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.

Подробное описание

Arm 1 will enroll patients who have been previously treated and failed on a JAK inhibitor or ineligible to receive treatment with a JAK inhibitor.

Arm 2 will enroll patients who are on a stable dose of ruxolitinib, but who have either lost response or had a suboptimal or plateau in response.

Arm 3 will enroll patients who have been previously treated with a JAK inhibitor (except momelotinib)

Вмешательства

• Препарат Nusivertib
  Oral PIM Inhibitor
• Препарат Ruxolitinib
  Oral JAK inhibitor
• Препарат Momelotinib
  Oral JAK inhibitor

Первичные конечные точки

• Determine the incidence of dose-limiting toxicities (DLTs) [Срок оценки: 28 days]
• Determine the incidence of treatment emergent adverse events [Срок оценки: From start of treatment to end of study]
• Assess patients for any evidence of preliminary activity by determining the number of patients with ≥ 35% spleen volume reduction (SVR35) [Срок оценки: From start of treatment to end of study]

Вторичные конечные точки (9)

• Number of participants achieving objective response by IWG-MRT response criteria [Срок оценки: From start of treatment to end of study]
• Number of participants who have ≥ 25% spleen volume reduction [Срок оценки: Every 12 weeks from cycle 1 day 1 through cycle 19 day 1, and then every 24 weeks therafter during treatment.]
• Number of participants with ≥ 50% improvement in total symptom score (TSS50) at week 24 [Срок оценки: 24 weeks]
• Determine the change in Patient Global Impression of Change (PGIC) at week 24 through end of study. [Срок оценки: After 24 weeks of treatment to end of study]
• Determine the incidence of QT interval changes [Срок оценки: 25 hours]
• Establish the half-life (t½) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib [Срок оценки: 24 hours]
• Establish the Area under the plasma concentration versus time curve (AUC) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib [Срок оценки: 24 hours]
• Establish the Peak Plasma Concentration (Cmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib [Срок оценки: 24 hours]
• Establish the Time of Maximum concentration observed (tmax) of nuvisertib monotherapy, in combination with ruxolitinib, and in combination with momelotinib [Срок оценки: 24 hours]

Критерии участия

Patients must meet all of the following inclusion criteria to be eligible:

Nuvisertib (TP-3654) Monotherapy Arm:

• Confirmed pathological diagnosis of primary myelofibrosis (PMF) or post-PV-MF/post-ET- MF and intermediate or high-risk primary or secondary MF
• Previously treated with JAK inhibitor(s) and is intolerant, resistant, refractory or has lost response to the JAK inhibitor(s) or is ineligible to be treated with JAK inhibitor
• Fulfill the following clinical laboratory parameters:
• Platelet count ≥ 25 x 10\^9 /L, without assistance of growth factors or platelet transfusions
• ANC ≥ 1 x 10\^9/L without assistance of granulocyte growth factors
• Peripheral blood blast count < 5%
• ECOG performance status ≤ 1
• Life expectancy ≥ 6 months
• Adequate renal function
• Adequate hepatic function
• Adequate coagulation function
• Splenomegaly (spleen volume of ≥ 450 cm3 by MRI or CT scan) within 2 weeks prior to Cycle 1 Day 1.
• Dose escalation: At least 2 symptoms measurable (score ≥ 1) using the MF-SAF
• Dose expansion: At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF

Nuvisertib (TP-3654) + Ruxolitinib Arm:

• Confirmed pathological diagnosis of PMF or post-PV-MF/post ET- MF and intermediate or high-risk primary or secondary MF
• On ruxolitinib treatment for ≥ 6 months, and on a stable dose of ruxolitinib (5 to 25 mg BID) for ≥ 8 weeks prior to the first dose of nuvisertib, but has either lost response or had a suboptimal or plateau in response
• Fulfills the following clinical laboratory parameters:
• Platelet count ≥ 50 × 10\^9/L (without assistance of growth factors or platelet transfusions)
• ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
• Peripheral blood blast count < 5% at screening
• Adequate renal function
• Adequate hepatic function
• Adequate coagulation function
• Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
• At least 2 symptoms measurable with each score ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
• ECOG performance status ≤ 1
• Life expectancy ≥ 6 months

Nuvisertib (TP-3654) + Momelotinib Arm

• Confirmed pathological diagnosis of PMF or post-PV-MF/post ET-MF and intermediate or high-risk primary or secondary MF
• Previously treated with an approved JAK inhibitor (except momelotinib) for PMF or Post-PV/ET MF for ≥ 12 weeks, or ≥ 4 weeks if JAK inhibitor therapy was complicated by a transfusion requirement of ≥ 4 units of red blood cells in 8 weeks, or Grade 3/4 AEs of thrombocytopenia, anemia, or hematoma
• Fulfills the following clinical laboratory parameters:
• Anemic, defined as Hb <10 g/dL or requiring RBC transfusion at baseline
• Platelet count ≥ 50 × 109/L (without assistance of growth factors or platelet transfusions)
• ANC ≥ 1 × 109/L without assistance of granulocyte growth factors
• Peripheral blood blast count < 5% at screening
• Adequate renal function
• Adequate hepatic function
• Adequate coagulation function
• Splenomegaly (spleen volume of ≥ 450 cm3 by MRI/CT scan) within 2 weeks prior to Cycle 1 Day 1
• At least 2 symptoms measurable with each score of ≥ 3 or a total average score of ≥ 10 per MFSAF v4.0
• ECOG performance status ≤ 1
• Life expectancy ≥ 6 months

Patients meeting any one of these exclusion criteria will be prohibited from participating in this study:

Nuvisertib (TP-3654) Monotherapy Arm:

• Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
• Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or not recovered adequately from from surgery prior to first dose.
• Splenic irradiation within 6 months prior to Screening or prior splenectomy.
• Prior allogeneic stem cell transplant within the last 6 months.
• Eligible for allogeneic bone marrow or stem cell transplantation.
• Unresolved Grade ≥ 2 non-hematological toxicity related to prior treatment
• History of symptomatic congestive heart failure, or myocardial infarction, or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; left ventricular ejection fraction (LVEF) < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1.
• Corrected QT interval > 480msec.
• Prior or concurrent malignancy that could interfere with the investigational regime.
• Known history of chronic liver disease, e.g. portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc.
• Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic antimicrobial within 1 week prior to Cycle 1 Day 1.
• Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
• Exhibited allergic reactions or sensitivity to nuvisertib, or similar compound.
• Medical condition or GI tract surgery that could impair absorption or result in short bowel syndrome with diarrhea.
• Systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to the first dose of study treatment (note: topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
• Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding.
• Pregnant or breastfeeding
• Currently receiving any other investigational agent.

Nuvisertib (TP-3654) + Ruxolitinib Arm:

• Received previous systemic antineoplastic therapy (other than ruxolitinib) or any other experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Note: Prior treatment with nuvisertib is not allowed. Hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
• Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited)
• Known allergic reactions or sensitivity to nuvisertib, or similar compound.
• Splenic irradiation within 6 months prior to Screening or prior splenectomy
• Prior allogeneic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
• Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible.)
• Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately prior to first dose.
• Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
• Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
• Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed).
• Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
• History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF <45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
• Corrected QTcF of > 480 msec
• Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
• History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
• Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
• Pregnant or breastfeeding

Nuvisertib (TP-3654) + Momelotinib Arm:

• Received previous systemic antineoplastic therapy or any experimental therapy within 2 weeks or 5 half-lives, whichever is longer, prior to Cycle 1 Day 1 (Notes: Prior treatment with momelotinib or nuvisertib is not allowed; in patients with ongoing JAK inhibitor therapy, ie, ruxolitinib, at screening, JAK inhibitor therapy must be tapered over a period of at least 1 week. Patients on a low dose of ruxolitinib (eg, 5 mg QD) may have a reduced taper period or no taper; hydroxyurea or anagrelide are allowed up to 24 hours prior to Cycle 1 Day 1).
• Received systemic steroid therapy (>10 mg daily prednisone or equivalent) within 1 week prior to Cycle 1 Day 1 (Note: Topical, inhaled, nasal, and ophthalmic steroids are not prohibited).
• Known allergic reactions or sensitivity to nuvisertib, momelotinib, or any structurally similar drug, or to any component of the formulations of either study intervention
• Splenic irradiation within 6 months prior to screening or prior splenectomy
• Prior allogenic stem cell transplant within the last 6 months (Note: Patients who have relapsed after 6 months post-transplant and do not have active GVHD are eligible).
• Eligible for allogeneic bone marrow or stem cell transplantation (Note: Patients who are not willing to undergo transplantation or for whom a suitable donor is not available are considered as transplant ineligible).
• Major surgery within 4 weeks prior to Cycle 1 Day 1 and/or have not recovered adequately from surgery prior to first dose.
• Active, uncontrolled bacterial, viral, or fungal infections, requiring parenteral antimicrobial within 1 week prior to Cycle 1 Day 1
• Chronic active or acute viral hepatitis A, B, or C infection (testing for hepatitis B and C are required)
• Known history of chronic liver disease (eg, portal hypertension or any of its complications, cirrhosis, Child-Pugh C, auto-immune hepatitis, alpha-1 anti-trypsin deficiency, Wilson's disease, etc) (Note: Abnormal liver morphology at baseline imaging may require additional testing, as needed)
• Unresolved Grade ≥ 2 non-hematological adverse events related to prior treatment (stable Grade 2 conditions may be permitted in consultation with the Sponsor)
• Presence of Grade ≥ 2 peripheral neuropathy
• History of myocardial infarction or symptomatic congestive heart failure or uncontrolled arrhythmia within 6 months prior to Cycle 1 Day 1; LVEF < 45% by echocardiogram within 4 weeks prior to Cycle 1 Day 1
• Corrected QTcF of > 480 msec
• Prior or concurrent malignancy that could interfere with the safety or efficacy assessment of the study intervention
• History of a medical condition or GI tract surgery that could impair absorption or could result in short bowel syndrome with diarrhea
• Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or thalassemia, or severe GI bleeding
• Pregnant or breastfeeding

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

США · 32 центра

• University of Alabama — Birmingham
• The University of Arizona Cancer Center — Tucson
• City of Hope — Duarte
• University of Southern California — Los Angeles
• Hoag Family Cancer Institute — Newport Beach
• Blood Cancer Center — Denver
• Yale School of Medicine — New Haven
• University of Florida Health Shands Cancer Hospital — Gainesville
• … и ещё 24 центра

Япония · 15 центров

• Aichi Medical University Hospital — Aichi
• Aomori Prefectural Central Hospital — Aomori
• National Cancer Center Hospital East — Chiba
• Kyushu University Hospital — Fukuoka
• Hokkaido University Hospital — Hokkaido
• Shonan Kamakura General Hospital — Kamakura
• University of Miyazaki Hospital — Miyazaki
• Okayama University Hospital — Okayama
• … и ещё 7 центров

Франция · 9 центров

• Centre Hospitalier Universitaire D'Amiens — Amiens
• CHU Angers — Angers
• Centre Hospitalier Lyon Sud — Lyon
• Hospitalier Universitaire (CHU) de Nice - Hopital de l'Archet — Nice
• Institut de cancerologie du Gard — Nîmes
• Institut de cancerologie du Gard — Nîmes
• Hospital Saint Louis — Paris
• University Hospital of Poitiers — Poitiers
• … и ещё 1 центр

Австралия · 7 центров

• Royal Adelaide Hospital — Adelaide
• Eastern Health Box Hill Hospital — Box Hill
• Monash University — Clayton
• St Vincent's Hospital Melbourne — Fitzroy
• Peter McCallum Center — Melbourne
• Epworth Healthcare — Richmond
• Icon Cancer Centre (Ashford Cancer Centre Research) — Adelaide

Италия · 7 центров

• Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo — Alessandria
• Istituto Nazionale Tumori, IRCCS Centro di Riferimento Oncologico di Aviano — Aviano
• IRCCS Azienda Ospedaliero -Universitaria Di Bologna - Dipartimento Malattie Oncologiche ed — Bologna
• ASST - Spedali Civili di Brescia — Brescia
• IRCCS istituto Romagnolo per lo studio dei tumori "Dino Amadori" — Meldola
• Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico — Milan
• Azienda Ospedaliera Universitaria Citta' Della Salute E della Scienza di Torino — Torino

Канада · 6 центров

• University of Calgary — Calgary
• St. Paul's Hospital Hematology/Oncology Research — Vancouver
• University of British Columbia — Vancouver
• Juravinski Cancer Center — Hamilton
• Princess Margaret Cancer Center — Toronto
• Jewish General Hospital — Montreal

Бельгия · 5 центров

• University Hospitals Leuven — Leuven
• ZNA Cadix — Antwerp
• ZNA Middelheim — Antwerp
• Universitair Ziekenhuis Gent — Ghent
• CHU de Liege — Liège

Великобритания · 4 центра

Список центров уточняется — проверьте первичный протокол.

Испания · 3 центра

Список центров уточняется — проверьте первичный протокол.

Германия · 2 центра

• Universitätsmedizin Halle — Halle
• Universitätsklinikum Schleswig-Holstein — Lübeck

Идентификаторы

NCT: NCT04176198 · BBI-TP-3654-102

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗